| Nov 15 |
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
|
| Nov 13 |
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?
|
| Nov 6 |
Merus to Present at Upcoming Investor Conferences
|
| Nov 5 |
Merus: Petosemtamab Set Up For December 2024 Data Presentation
|
| Nov 5 |
Merus says FDA extended review period for cancer drug
|
| Nov 5 |
Merus Receives FDA extension of PDUFA for zenocutuzumab
|
| Nov 2 |
Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Oct 31 |
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
|
| Oct 31 |
Merus GAAP EPS of -$1.46, revenue of $11.77M
|
| Oct 31 |
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
|
